Abstract
The idea of using small RNA fragments (oligonucleotides) for therapeutic purposes dates back to the 1990s, following the landmark discoveries on the mechanisms of gene silencing and RNA-interference (RNA-i). However, the first applications in medicine were hampered by difficulties in chemical stabilization and efficient delivery to target tissues. Recent advances in chemical manipulation of oligonucleotides have, at least partially, bypassed such obstacles. In particular, conjugation with ligands for specific receptors allows the selective uptake of oligonucleotides by critical cells (e.g., hepatocytes), where they inhibit the synthesis of the target protein by binding the complementary mRNA and inducing its degradation. In parallel, next-generation sequencing (NGS) studies at population levels have identified a number of key molecular targets, mainly through the discovery of “human knock-outs,” i.e., subjects lacking a given protein because of nonsense mutations in the corresponding gene. Such highly informative individuals are often healthy, or even protected from the development of certain diseases. Indeed, subjects with null mutations in certain genes controlling lipoprotein metabolism like PCSK9 or ANGPTL-3 have a lower risk of cardiovascular disease. Since the complete absence of such proteins does not appear to carry any negative health effect, the corresponding genes are ideal candidates for the silencing approach. Pilot clinical trials with long acting anti-PCSK9 or anti-ANGPTL-3 oligonucleotides have yielded very promising results, so that their use as “vaccines” against atherosclerosis has been suggested in the future. As therapeutic oligonucleotides can virtually target innumerable proteins, their increasing development is predicted to substantially expand the repertoire of the “biological drugs,” in addition to, or even substituting, more consolidated approaches like monoclonal antibodies.
References
Girelli D, Piubelli C, Martinelli N, Corrocher R, Olivieri O (2017) A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. Eur J Intern Med 41:10–17
Bennett CF, Baker BF, Pham N, Swayze E, Geary RS (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81–105
Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238–248
Khvorova A (2017) Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med 376:4–7
https://www.nobelprize.org/nobel_prizes/medicine/laureates/2006/. Accessed 21 Feb 2018
Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q et al (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958–16961
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41–51
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13:828–851
Holderfield M (2017) Efforts to develop KRAS inhibitors. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a031864
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N et al (2017) Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med 9(394). https://doi.org/10.1126/scitranslmed.aal5253
Girelli D, Martinelli N, Peyvandi F, Olivieri O (2009) Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging “golden dozen” loci. Semin Thromb Hemost 35:671–682
Stitziel NO, Kathiresan S (2017) Leveraging human genetics to guide drug target discovery. Trends Cardiovasc Med 27:352–359
Kaiser J (2014) The hunt for missing genes. Science 344:687–689
Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA et al (2017) Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544:235–239
Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE et al (2017) ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol 69:2054–2063
Plenge RM (2017) Biomedicine: human genes lost and their functions found. Nature 544:171–172
Khera AV, Kathiresan S (2017) Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 18:331–344
Monteleone G, Pallone F (2015) Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 372:2461
Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G et al (2017) Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord 27:1084–1086
Nelson SF, Miceli MC (2017) FDA approval of eteplirsen for muscular dystrophy. JAMA J Am Med Assoc 317:1480
Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM et al (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord 28:4–15
Buller HR, Gailani D, Weitz JI (2015) Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med 372:1672
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253
Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711
Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W et al (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373:438–447
Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54:133–146
Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH et al (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 33:1142–1149
Natarajan P, Kathiresan S (2016) PCSK9 inhibitors. Cell 165:1037
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376:1430–1440
Ummarino D (2017) Dyslipidaemia: anti-PCSK9 vaccines to halt atherosclerosis. Nat Rev Cardiol 14:442–443
Acknowledgements
DG, OO, and NM are recipients of research grants from the Cariverona Foundation. Funding was provided by Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (IT) (Grant no. 2015.0872) and Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (Grant no. 2014.0851).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
None.
Rights and permissions
About this article
Cite this article
Girelli, D., Busti, F., Marchi, G. et al. Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist. Intern Emerg Med 13, 313–318 (2018). https://doi.org/10.1007/s11739-018-1810-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-018-1810-5